HCPCS code J1830 – Interferon beta-1b injection

Key takeaways

HCPCS code J1830 bills interferon beta-1b (Betaseron, Extavia) at 0.25 mg per unit, so the full maintenance dose is 1 unit.

Betaseron is a subcutaneous injection for relapsing forms of multiple sclerosis, given every other day after a six-week titration.

Medicare contractors list J1830 on their self-administered drug exclusion lists, so Part B generally does not pay for the drug.

Pair J1830 with a specific G35 subcode, such as G35.A, because the old G35 code stopped being valid on October 1, 2025.

Report the 11-digit Betaseron NDC with the N4 qualifier, and add JB only where a payer asks for the subcutaneous route modifier.

HCPCS code J1830: Definition and code description

HCPCS code J1830 reports injection, interferon beta-1b, 0.25 mg. Interferon beta-1b is sold as Betaseron by Bayer, and was also sold as Extavia, a Novartis-labeled version of the same drug.

Patients inject it under the skin every other day to treat relapsing forms of multiple sclerosis (MS). One unit of J1830 equals 0.25 mg, which is the full recommended dose.

The official descriptor carries a Medicare condition. The code may be used when the drug is given under the direct supervision of a physician. It is not for use when the drug is self-administered.

J-codes are HCPCS Level II codes maintained by CMS for drugs given other than by mouth. They cover the drug only, so the injection service goes on its own line with a CPT code.

J1830 code details at a glance

What interferon beta-1b (Betaseron) is used for

The FDA label approves Betaseron for relapsing forms of MS in adults. That covers clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Primary progressive MS and non-active secondary progressive MS sit outside the label. A claim for those diagnoses is off-label, and most payers will want a medical necessity case before they pay.

Betaseron ships as a kit for home use. Each carton holds a 0.3 mg vial of powder, a prefilled syringe with 1.2 mL of diluent, and a vial adapter. Once mixed, 1 mL contains 0.25 mg, according to the Betaseron prescribing information.

Because patients inject themselves at home, most J1830 claims come from one setting. That is the training visit, where a nurse supervises the first injections and teaches the technique.

How to report units for J1830

Report J1830 in units of 0.25 mg, so the full 0.25 mg maintenance dose is 1 unit. The label starts patients at a quarter of that dose and steps up over six weeks.

A titration dose smaller than 0.25 mg still reports as 1 unit, the usual rule when a dose is below the billing unit. The rest of the vial is discarded, so check how the payer wants that waste reported.

The vial holds 0.3 mg, but the labeled dose drawn up is 1 mL, or 0.25 mg. Bill the dose given, which keeps the line at 1 unit. The extra content in the vial is never billed as a second unit.

NDC reporting for J1830

Medicare and most commercial payers require a National Drug Code (NDC) on every drug claim line. For J1830, the NDC identifies which Betaseron package the dose came from.

These NDCs come from the FDA NDC Directory and DailyMed listing for Betaseron. Extavia no longer has an active listing in the FDA NDC Directory, so a current claim will almost always carry a Betaseron NDC.

Practices focused on submitting a clean claim enter the NDC in this format:

• Qualifier: N4, placed directly before the NDC.
• NDC: The 11-digit 5-4-2 number from the package used, with no hyphens on electronic claims.
• Unit of measure: UN (unit) for a kit, unless the payer specifies another unit.
• Quantity: The number of kits used, which is 1 for a single injection.

Copy the NDC from the package in hand, not from a saved favorite. An NDC that does not match the dispensed product is a common reason for a drug line to deny.

ICD-10-CM codes to pair with J1830

J1830 needs a specific multiple sclerosis code from the G35 family. On October 1, 2025, the single code G35 became a category, and claims now need one of its subcodes.

Clinically isolated syndrome is on Betaseron’s label, but it has no G35 subcode of its own. Code the condition the neurologist documents, and confirm which code the payer accepts before the first claim.

A claim that still carries plain G35 is invalid for dates of service from October 1, 2025. Update templates and favorites lists so the old code cannot slip back onto a claim. Where the record does not name the MS type, G35.D is valid but tends to draw payer questions.

Modifiers used with J1830

J1830 has no single required modifier, so the right choice depends on the payer and on who pays. These are the ones that come up on interferon beta-1b claims.

CMS requires JW or JZ on single-dose vial drugs that Part B pays separately. A self-administered drug that Medicare excludes is not paid separately, so those modifiers matter mainly for commercial plans.

Medicare coverage and the self-administered drug exclusion

Medicare Part B generally does not pay for J1830. Part B excludes drugs that are usually self-administered, under the Medicare Benefit Policy Manual, Chapter 15, section 50.2.

Each Medicare Administrative Contractor (MAC) publishes a self-administered drug (SAD) exclusion list. J1830 (Betaseron) appears on the lists from Noridian, Palmetto GBA and CGS, including Noridian’s exclusion list (A53032).

Once a drug is on the SAD list, the exclusion applies even when a nurse gives the dose in the office. The descriptor’s “direct supervision” wording does not override the exclusion.

Most Medicare patients get Betaseron through a Part D plan instead, dispensed by a specialty pharmacy. The practice then bills only its own services, such as the visit or the injection training.

Check your own MAC’s list before you bill. The lists are updated through published articles, and each MAC sets its own effective dates.

Commercial and Medicaid coverage

Commercial plans and Medicaid programs usually cover Betaseron under the pharmacy benefit. A plan may still accept J1830 on a medical claim for a supervised dose, such as a training visit.

Prior authorization is standard for MS disease-modifying therapies. Typical criteria include:

• A neurologist’s confirmed diagnosis of a relapsing form of MS, with the MS type recorded
• Supporting clinical history, such as relapse dates or MRI findings
• Prescriber details on the dose, the titration plan and the dosing frequency
• Step therapy records where the plan prefers another disease-modifying therapy first

Policies change at plan renewal, so check the current criteria before each new authorization. Record the approval number and its expiry date before the supervised injection is booked.

Across the three payer routes, only the commercial or Medicaid branch usually puts J1830 on a medical claim.

Administration codes and place of service

Bill the injection itself with CPT 96372, the code for a therapeutic subcutaneous or intramuscular injection. It goes on a separate line from J1830.

When Medicare excludes the drug, check your MAC’s guidance on whether the 96372 line is payable. Teaching time may also be part of an evaluation and management visit rather than a separate charge.

How J1830 compares with other MS injectable codes

The most common wrong-code error is billing interferon beta-1a under J1830. Beta-1a and beta-1b are different drugs with different codes and billing units. Avonex, an intramuscular beta-1a, bills under J1826 at 30 mcg per unit.

Use the AAPC HCPCS Level II code lookup to cross-check descriptors when the order names a brand you do not recognize. Q3027, Q3028 and J1595 sit on Noridian’s self-administered drug exclusion list too, so the same Medicare problem applies to them.

Common J1830 claim denials and how to fix them

Most J1830 denials trace back to one of a handful of causes. Good denial management strategies fix each cause at the workflow level, so the same error does not return on the next claim.

J1830 documentation requirements

Documentation falls into two groups. One set must be in the chart on the day of service, and the other is needed only if the claim is audited.

Required at the time of service:

• A neurologist’s diagnosis that names the MS type, so the G35 subcode is supported
• An order naming interferon beta-1b, the dose, the subcutaneous route and every-other-day dosing
• Injection notes with the dose given, the injection site, the NDC, the lot number and the expiry date
• Who supervised the injection, and the self-injection teaching delivered
• The prior authorization number, where the payer requires one

Required only if audited:

• Clinical history supporting a relapsing form of MS, such as relapse dates or MRI reports
• Liver function tests and blood counts, which the label recommends monitoring
• Records of earlier disease-modifying therapies, for step therapy appeals

A structured superbill that captures the drug, dose, NDC and lot number at the point of care reduces audit risk. It also speeds up resubmission when a denial lands.

How Pabau supports J1830 billing and documentation

Billing J1830 means checking the payer before the visit, then recording the NDC and dose during it. Many practices still track those steps across a spreadsheet, a paper log and the billing system.

Pabau, the practice management and billing platform we build, keeps the injection note, the charge and the claim in one patient record. Its claims management software tracks each claim through to payment and groups denials by reason.

The outcome is fewer drug lines sent to the wrong payer, and a record that answers an audit request without a search through paper files.

Bill specialty injectables to the right payer

Pabau keeps the injection note, NDC and charge in one record, then tracks each claim and denial by reason code. Interferon beta-1b claims go to the correct payer the first time.

Book a demo

Conclusion

J1830 is a small code with an outsized coverage question. Before you bill the dose, find out who pays for it, because Medicare Part B usually will not.

Get that decision right, and the rest of the claim is mechanical. Use 1 unit, a Betaseron NDC, a specific G35 subcode, and CPT 96372 on its own line. Get it wrong, and no amount of clean coding will rescue the claim.

Book a demo to see how Pabau helps your practice route specialty injectable claims to the right payer and keep their documentation audit-ready.

Continue your research

Need a framework for tracking drug claim denials? Denial management in healthcare covers the workflow steps to categorize, appeal, and prevent recurring claim rejections.

Want to understand how J-code drug billing fits the bigger picture? What is revenue cycle management explains the end-to-end process from patient encounter to collected payment.

Managing billing compliance across multiple payers? Medical billing compliance outlines the documentation and audit-readiness standards that protect practices during payer reviews.

Frequently asked questions